Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib in MET-mutated PSC and NSCLC
NCT02897479Phase 2Unknown
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of savolitinib in pulmonary sarcomatoid carcinoma (PSC) and non-small cell lung cancer (NSCLC), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
savolitinib
03
Conditions
pulmonary sarcomatoid carcinoma (PSC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02897479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897479.